Downregulation of MiR-154 in Human Glioma and Its Clinicopathological and Prognostic Significance

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2016 Jul 16

PMID 27417886

Citations 9

Authors

Lingling Wang

Lei Wu

Jiang Wu

Affiliations

Soon will be listed here.

Abstract

Objective MicroRNA-154 (miR-154) was previously reported to be downregulated in several types of human cancers and may act as a tumour suppressor. This study aimed to measure miR-154 levels and determine its clinical significance in human glioma. Methods This retrospective study analysed fresh human glioma specimens and non-neoplastic brain tissues using real-time quantitative reverse transcription-polymerase chain reaction to determine the relative levels of miR-154. The association between miR-154 levels and various clinicopathological characteristics and survival was analysed. Results A total of 115 patients with gliomas and 115 non-neoplastic brain tissues were examined. MiR-154 levels were significantly downregulated in gliomas compared with non-neoplastic brain tissues. Low levels of miR-154 were associated with high World Health Organization grade, large tumour size (≥ 5 cm), a low Karnofsky performance status score (< 80), and a shorter overall survival. Multivariate analyses using the Cox proportional hazards regression model confirmed that decreased miR-154 level was an independent predictor of a poor prognosis. Conclusions These results suggest that miR-154 downregulation may be involved in glioma formation and progression, and that miR-154 might serve as a potential prognostic biomarker for patients with this disease.

Citing Articles

Influences HNSCC Development and Progression through Regulation of the Epithelial-to-Mesenchymal Transition Process and Could Be Used as a Potential Biomarker.

Tomaszewska W, Kozlowska-Maslon J, Baranowski D, Perkowska A, Szalkowska S, Kazimierczak U Biomedicines. 2021; 9(12).

PMID: 34944712 PMC: 8698850. DOI: 10.3390/biomedicines9121894.

PIWI-interacting RNAs and PIWI proteins in glioma: molecular pathogenesis and role as biomarkers.

Tamtaji O, Behnam M, Pourattar M, Hamblin M, Mahjoubin-Tehran M, Mirzaei H Cell Commun Signal. 2020; 18(1):168.

PMID: 33109195 PMC: 7590611. DOI: 10.1186/s12964-020-00657-z.

MicroRNA-154: A Novel Candidate for Diagnosis and Therapy of Human Cancers.

Nazarizadeh A, Mohammadi F, Alian F, Faraji P, Nourbakhsh M, Alizadeh-Fanalou S Onco Targets Ther. 2020; 13:6603-6615.

PMID: 32753896 PMC: 7354082. DOI: 10.2147/OTT.S249268.

MicroRNA-154-5p regulates the HPV16 E7-pRb pathway in Cervical Carcinogenesis by targeting CUL2.

Zhao W, Liu Y, Zhang L, Ding L, Li Y, Zhang H J Cancer. 2020; 11(18):5379-5389.

PMID: 32742484 PMC: 7391205. DOI: 10.7150/jca.45871.

Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.

Bolandghamat Pour Z, Nourbakhsh M, Mousavizadeh K, Madjd Z, Ghorbanhosseini S, Abdolvahabi Z BMC Cancer. 2019; 19(1):1027.

PMID: 31675930 PMC: 6824125. DOI: 10.1186/s12885-019-6221-0.

References

Xin C, Zhang H, Liu Z . miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2. Mol Cell Biochem. 2013; 387(1-2):271-7. DOI: 10.1007/s11010-013-1892-3. View

Liu H, Xing A, Chen X, Ma R, Wang Y, Shi D . MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers. Oncotarget. 2015; 6(35):37458-70. PMC: 4741941. DOI: 10.18632/oncotarget.6059. View

Lin X, Yang Z, Zhang P, Shao G . miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo. Oncol Rep. 2015; 33(6):3053-60. DOI: 10.3892/or.2015.3895. View

Friendlander A, Ettinger R . Karnofsky performance status scale. Spec Care Dentist. 2009; 29(4):147-8. DOI: 10.1111/j.1754-4505.2009.00088.x. View

Abrahamsson A, Dabrosin C . Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo. Oncotarget. 2015; 6(26):22959-69. PMC: 4673212. DOI: 10.18632/oncotarget.4038. View

Dontula R, Dinasarapu A, Chetty C, Pannuru P, Herbert E, Ozer H . MicroRNA 203 Modulates Glioma Cell Migration via Robo1/ERK/MMP-9 Signaling. Genes Cancer. 2013; 4(7-8):285-96. PMC: 3807644. DOI: 10.1177/1947601913500141. View

Macfarlane L, Murphy P . MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2011; 11(7):537-61. PMC: 3048316. DOI: 10.2174/138920210793175895. View

Fabian M, Sonenberg N, Filipowicz W . Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010; 79:351-79. DOI: 10.1146/annurev-biochem-060308-103103. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

10.

Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H . miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem. 2013; 379(1-2):69-75. DOI: 10.1007/s11010-013-1628-4. View

11.

Taylor L . Diagnosis, treatment, and prognosis of glioma: five new things. Neurology. 2010; 75(18 Suppl 1):S28-32. DOI: 10.1212/WNL.0b013e3181fb3661. View

12.

Xu L, Fengji L, Changning L, Liangcai Z, Yinghui L, Yu L . Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. PLoS One. 2015; 10(11):e0142433. PMC: 4659652. DOI: 10.1371/journal.pone.0142433. View

13.

Louis D . Molecular pathology of malignant gliomas. Annu Rev Pathol. 2007; 1:97-117. DOI: 10.1146/annurev.pathol.1.110304.100043. View

14.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

15.

Formosa A, Markert E, Lena A, Italiano D, Finazzi-Agro E, Levine A . MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2013; 33(44):5173-82. DOI: 10.1038/onc.2013.451. View

16.

Li G, Zhang Z, Tu Y, Jin T, Liang H, Cui G . Correlation of microRNA-372 upregulation with poor prognosis in human glioma. Diagn Pathol. 2013; 8:1. PMC: 3551676. DOI: 10.1186/1746-1596-8-1. View

17.

Kai Y, Qiang C, Xinxin P, Miaomiao Z, Kuailu L . Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol. 2015; 13:195. PMC: 4472271. DOI: 10.1186/s12957-015-0607-5. View

18.

He J, Deng Y, Yang G, Xie W . MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol. 2013; 108(2):121-5. DOI: 10.1002/jso.23315. View

19.

Garzon R, Fabbri M, Cimmino A, Calin G, Croce C . MicroRNA expression and function in cancer. Trends Mol Med. 2006; 12(12):580-7. DOI: 10.1016/j.molmed.2006.10.006. View

20.

Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H . miR-154 inhibits prostate cancer cell proliferation by targeting CCND2. Urol Oncol. 2013; 32(1):31.e9-16. DOI: 10.1016/j.urolonc.2012.11.013. View